Potential JAK2 Inhibitors from Selected Natural Compounds: A Promising Approach for Complementary Therapy in Cancer Patients

Table 5

Predicted ADMET for top-ranked herbal metabolites in this study.

Ligand name	GI abs	BBB permeant	P-gp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	CYP2D6 inhibitor	CYP3A4 inhibitor	Carcinogenesis	Bioavailability score
Orientin	Low	No	No	No	No	No	No	No	High safety	0.17
Kaempferol 3-rutinoside-4′-glucoside	Low	No	Yes	No	No	No	No	No	High safety	0.17
Vitexin	Low	No	No	No	No	No	No	No	High safety	0.55
Isoquercitrin	Low	No	No	No	No	No	No	No	High safety	0.17
Quercetin-3-rhamnoside	Low	No	Yes	No	No	No	No	No	High safety	0.17
Quercitrin	Low	No	Yes	No	No	No	No	No	High safety	0.17
Nicotiflorin	Low	No	No	No	No	No	No	No	High safety	0.17
Kaempferol 7-O-glucoside	Low	No	No	No	No	No	No	No	High safety	0.17
Astragalin	Low	No	No	No	No	No	No	No	High safety	0.17
Cynaroside	Low	No	Yes	No	No	No	No	No	High safety	0.17
Apigenin-7-glucoside	Low	No	Yes	No	No	No	No	No	High safety	0.55
Pulmatin	Low	No	Yes	No	No	No	No	No	High safety	0.55
Emodin-8-glucoside	Low	No	Yes	No	No	No	No	No	High safety	0.55
Chlorogenic acid	Low	No	No	No	No	No	No	No	High safety	0.11
Cynarin	Low	No	Yes	No	No	No	No	No	High safety	0.11
Rosmarinic acid	Low	No	No	No	No	No	No	No	High safety	0.56

GI, gastrointestinal; abs, absorption; BBB, blood–brain barrier; P-gp, p-glycoprotein; CYP, cytochrome p-450.